iBio, Inc. Statistics
Total Valuation
iBio, Inc. has a market cap or net worth of $61.84 million. The enterprise value is -$24.00 million.
| Market Cap | 61.84M |
| Enterprise Value | -24.00M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iBio, Inc. has 64.31 million shares outstanding. The number of shares has increased by 891.14% in one year.
| Current Share Class | 64.31M |
| Shares Outstanding | 64.31M |
| Shares Change (YoY) | +891.14% |
| Shares Change (QoQ) | +21.53% |
| Owned by Insiders (%) | 1.32% |
| Owned by Institutions (%) | 38.14% |
| Float | 52.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 643.07 |
| Forward PS | 3,857.66 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.85, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.85 |
| Quick Ratio | 7.50 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -568.64 |
Financial Efficiency
Return on equity (ROE) is -65.70% and return on invested capital (ROIC) is -35.42%.
| Return on Equity (ROE) | -65.70% |
| Return on Assets (ROA) | -30.80% |
| Return on Invested Capital (ROIC) | -35.42% |
| Return on Capital Employed (ROCE) | -34.50% |
| Weighted Average Cost of Capital (WACC) | 10.86% |
| Revenue Per Employee | $4,348 |
| Profits Per Employee | -$1.44M |
| Employee Count | 23 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.04% in the last 52 weeks. The beta is 1.26, so iBio, Inc.'s price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | +15.04% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 1.80 |
| Relative Strength Index (RSI) | 25.90 |
| Average Volume (20 Days) | 717,675 |
Short Selling Information
The latest short interest is 4.94 million, so 7.68% of the outstanding shares have been sold short.
| Short Interest | 4.94M |
| Short Previous Month | 5.20M |
| Short % of Shares Out | 7.68% |
| Short % of Float | 9.47% |
| Short Ratio (days to cover) | 6.96 |
Income Statement
In the last 12 months, iBio, Inc. had revenue of $100,000 and -$33.04 million in losses. Loss per share was -$0.32.
| Revenue | 100,000 |
| Gross Profit | 100,000 |
| Operating Income | -30.14M |
| Pretax Income | -33.04M |
| Net Income | -33.04M |
| EBITDA | -29.49M |
| EBIT | -30.14M |
| Loss Per Share | -$0.32 |
Balance Sheet
The company has $88.04 million in cash and $2.20 million in debt, with a net cash position of $85.84 million or $1.33 per share.
| Cash & Cash Equivalents | 88.04M |
| Total Debt | 2.20M |
| Net Cash | 85.84M |
| Net Cash Per Share | $1.33 |
| Equity (Book Value) | 85.71M |
| Book Value Per Share | 1.54 |
| Working Capital | 80.48M |
Cash Flow
In the last 12 months, operating cash flow was -$23.22 million and capital expenditures -$578,000, giving a free cash flow of -$23.80 million.
| Operating Cash Flow | -23.22M |
| Capital Expenditures | -578,000 |
| Depreciation & Amortization | 646,000 |
| Net Borrowing | -774,000 |
| Free Cash Flow | -23.80M |
| FCF Per Share | -$0.37 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -30,138.00% |
| Pretax Margin | -33,044.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iBio, Inc. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -891.14% |
| Shareholder Yield | -891.14% |
| Earnings Yield | -51.38% |
| FCF Yield | -37.00% |
Analyst Forecast
The average price target for iBio, Inc. is $5.69, which is 491.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.69 |
| Price Target Difference | 491.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -41.52% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 29, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iBio, Inc. has an Altman Z-Score of -3.07 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.07 |
| Piotroski F-Score | 2 |